TARC After alloSCT in Hodgkin's Lymphoma

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Status: Completed

Conditions: Hodgkin's Lymphoma Patients Who Underwent an Allogeneic Stem Cell Transplantation

Treatments: Other: no treatment

Study type: Observational

Funder types: Other

Identifiers

NCT02069639

TARC

Details and patient eligibility

About

Relapsed and refractory Hodgkin's lymphoma (HL) patients may experience long-term survival after allogeneic transplant (alloSCT), but disease recurrence represents the main cause of treatment failure. PET (positron-emission tomography) -positive patients after alloSCT have a dismal outcome. Serum TARC (thymus and activation-regulated chemokine) is produced by Reed-Sternberg cells and may be a marker of disease. Our study was aimed at assessing whether TARC levels after alloSCT were correlated to disease status and whether TARC monitoring could increase the ability to predict relapse.

Enrollment: 22 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hodgkin's lymphoma patients who underwent an alloSCT at Fondazione IRCCS Istituto Nazionale dei Tumori and who were monitored by PET and TARC before and after alloSCT from 2009

Exclusion criteria

• Hodgkin's lymphoma patients who underwent an alloSCT who were not monitored by PET or/and TARC

Trial design

22 participants in 1 patient group

no treatment

Treatment:

Other: no treatment